<code id='99AD8B65B5'></code><style id='99AD8B65B5'></style>
    • <acronym id='99AD8B65B5'></acronym>
      <center id='99AD8B65B5'><center id='99AD8B65B5'><tfoot id='99AD8B65B5'></tfoot></center><abbr id='99AD8B65B5'><dir id='99AD8B65B5'><tfoot id='99AD8B65B5'></tfoot><noframes id='99AD8B65B5'>

    • <optgroup id='99AD8B65B5'><strike id='99AD8B65B5'><sup id='99AD8B65B5'></sup></strike><code id='99AD8B65B5'></code></optgroup>
        1. <b id='99AD8B65B5'><label id='99AD8B65B5'><select id='99AD8B65B5'><dt id='99AD8B65B5'><span id='99AD8B65B5'></span></dt></select></label></b><u id='99AD8B65B5'></u>
          <i id='99AD8B65B5'><strike id='99AD8B65B5'><tt id='99AD8B65B5'><pre id='99AD8B65B5'></pre></tt></strike></i>

          entertainment

          entertainment

          author:knowledge    Page View:13249
          The headquarter of Biotechnology company Ionis Pharmaceuticals, consists of glass windows, pale yellow exteriors and plants outside the building — biotech coverage from STAT
          courtesy Ionis Pharmaceuticals

          Ionis Pharmaceuticals, a California company that pioneered a whole class of RNA-targeted medicines, reported on Friday that a pair of late-stage trials showed that its experimental therapy for hereditary angioedema benefitted patients — including those taking drugs currently on the market.

          In one of the Phase 3 trials, dubbed OASIS, patients with hereditary angioedema, a rare disease characterized by severe bouts of swelling, were given injections of donidalorsen either monthly or every two months. Those in the former group had an 81% lower monthly rate of swelling attacks after 25 weeks than patients given a placebo, while the reduction compared to placebo was 55% for those treated every two months.

          advertisement

          The other study, OASISplus, found that donidalorsen’s benefits deepened and converged after up to an additional year of treatment, with swelling attack rates dropping by 92% to 93% regardless of how often patients were dosed. Notably, this study also tracked patients who switched over to donidalorsen from existing therapies meant to prevent swelling attacks, including drugs sold by Takeda and BioCryst Pharmaceuticals. Patients who switched to the Ionis drug saw their swelling attack rates drop by 62% compared to previous treatment.

          STAT+ Exclusive Story

          Already have an account? Log in

          STAT+

          This article is exclusive to STAT+ subscribers

          Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

          Already have an account? Log in

          Already have an account? Log in

          Monthly

          $39

          Totals $468 per year

          $39/month Get Started

          Totals $468 per year

          Starter

          $30

          for 3 months, then $39/month

          $30 for 3 months Get Started

          Then $39/month

          Annual

          $399

          Save 15%

          $399/year Get Started

          Save 15%

          11+ Users

          Custom

          Savings start at 25%!

          Request A Quote Request A Quote

          Savings start at 25%!

          2-10 Users

          $300

          Annually per user

          $300/year Get Started

          $300 Annually per user

          View All Plans

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          Wikipedia

          Sports medicine is finally prioritizing gender equality
          Sports medicine is finally prioritizing gender equality

          MollyFergusonforSTATWhencyclistAlisonTetrickjoinedthesport’sprofessionalranks,shereceivedtheperkstha

          read more
          Judge orders hearing on Trump's motion to disqualify Fulton County DA
          Judge orders hearing on Trump's motion to disqualify Fulton County DA

          5:51RepublicanpresidentialcandidateformerpresidentDonaldTrumpspeaksattheRepublicanPartyofIowa's2023L

          read more
          Affirmative action in medical school literally saved lives
          Affirmative action in medical school literally saved lives

          AdobeThepastseveralmonthshavebeengrimforhealthintheU.S.InDecember,theCentersforDiseaseControlandPrev

          read more

          Venture capitalist Bob Kocher on the state of digital health

          BobKocher,apartneratventurecapitalfirmVenrock,speakingatSTAT'sBreakthroughSummitinSanFrancisco.Sarah